- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Interventions
- NS-018
- Drug
- Lead sponsor
- NS Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • San Diego, California • Jacksonville, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 29,129
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dyslipidemia
- Interventions
- LCP-AtorFen, atorvastatin, fenofibrate
- Drug
- Lead sponsor
- Asahi Kasei Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Renal Failure
- Interventions
- Standard dose of dialysis, High dose of dialysis
- Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma
- Interventions
- Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg), Omaveloxolone Capsules (10 mg/capsule), Omaveloxolone Capsules (50 mg/capsule)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 10
- States / cities
- Mobile, Alabama • Fayetteville, Arkansas • Aurora, Colorado + 7 more
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- NNC9204-0530, liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Lincoln, Nebraska
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Interventions
- Nab paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Aurora, Colorado + 1 more
- Conditions
- Insulin Resistance
- Interventions
- BFKB8488A, Placebo
- Drug · Other
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Opioid Use, Opioid Use Disorder, Cocaine Use, Cocaine Use Disorder
- Interventions
- DynamiCare Health, Methadone Treatment-As-Usual
- Behavioral · Drug
- Lead sponsor
- Friends Research Institute, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland
- Conditions
- Depressive Disorder, Smoking
- Interventions
- fixed dose varenicline, varenicline
- Drug
- Lead sponsor
- Butler Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Alopecia Areata
- Interventions
- Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more
- Conditions
- Candidiasis
- Interventions
- Fluconazole Powder
- Drug
- Lead sponsor
- Sutphin Drugs
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Jamaica, New York
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Interventions
- filgrastim, amifostine trihydrate, cisplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 84
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 51 more
- Conditions
- Metastatic Pancreatic Cancer, Pancreatic Cancer
- Interventions
- IMMU-107, placebo, Gemcitabine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 42
- States / cities
- Gilbert, Arizona • Duarte, California • Long Beach, California + 33 more
- Conditions
- Oligodendroglioma, Astrocytoma, Malignant Glioma
- Interventions
- PF-06840003
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Boston, Massachusetts • Albuquerque, New Mexico + 3 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- AZD1152, LDAC (low dose cytosine arabinoside)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Houston, Texas
- Conditions
- Parkinson's Disease (Disorder)
- Interventions
- IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
- Drug · Other
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
- Conditions
- Diabetic Macular Edema
- Interventions
- triamcinolone acetonide
- Drug
- Lead sponsor
- SurModics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Santa Barbara, California • Detroit, Michigan + 1 more
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, High-risk Neuroblastoma
- Interventions
- Autologous hALK.CAR T cells
- Biological
- Lead sponsor
- Roberto Chiarle
- Other
- Eligibility
- 12 Months to 29 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
- Interventions
- Selumetinib, Sirolimus
- Drug
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 2 more
- Conditions
- Advanced Unresectable Solid Tumors
- Interventions
- Andes-1537 for Injection
- Drug
- Lead sponsor
- Andes Biotechnologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Posttraumatic Stress Disorder, Major Depressive Disorder
- Interventions
- LDAEP, Placebo, sertraline
- Diagnostic Test · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charleston, South Carolina
- Conditions
- Breast Cancer
- Interventions
- LOXO-783, Fulvestrant, Imlunestrant, Abemaciclib, Anastrozole, Exemestane, or Letrozole, Paclitaxel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Oncology, Acute Myeloid Leukemia
- Interventions
- Open Label LAM-003
- Drug
- Lead sponsor
- IRulya Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Influenza
- Interventions
- GSK investigational vaccine GSK1557482A, Fluzone®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 2,116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Benton, Arkansas • Huntington Beach, California + 25 more